Novo Nordisk / Aradigm link on insulin device:
This article was originally published in Clinica
Novo Nordisk and Aradigm plan the joint development of a pulmonary insulin delivery system, based on Aradigm's AerX drug delivery system. The deal includes other glucose-regulatory compounds as well as two other, unnamed and unrelated therapeutics. Novo gains worldwide rights to any of the resulting products and Aradigm gains $9 million in upfront payments and equity investment, with a total of $50 million in possible milestone payments thereafter. Aradigm is based in Hayward, California.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
The first of around 260 patients for a clinical trial comparing its PB006 natalizumab biosimilar candidate to Biogen’s Tysabri reference brand have been recruited by Polpharma Biologics, which has just added Karsten Roth and Alexandra Moulson to its team.